C1inhibitor (human) (Cinryze®)

Assessment Status Rapid Review complete
HTA ID -
Drug C1inhibitor (human)
Brand Cinryze®
Indication Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment
Assessment Process
Rapid review commissioned 22/10/2012
Rapid review completed 14/11/2012
Rapid review outcome Full pharmacoeconomic assessment not recommended